Strong association of interleukin-6 and lipopolysaccharide-binding protein with severity of adverse reactions after diethylcarbamazine treatment of microfilaremic patients

被引:33
作者
Haarbrink, M
Abadi, GK
Buurman, WA
Dentener, MA
Terhell, AJ
Yazdanbakhsh, M
机构
[1] Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands
[2] Maastricht Univ, Dept Surg, Maastricht, Netherlands
[3] Maastricht Univ, Dept Pulmonol, Maastricht, Netherlands
[4] Hasanuddin Univ, Dept Parasitol, Ujung Pandang, Indonesia
关键词
D O I
10.1086/315735
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To assess the involvement of inflammatory mediators in the development of adverse reactions in filarial patients undergoing treatment, 29 microfilaremic subjects were treated with diethylcarbamazine (DEC). Before and at serial time points after initiation of treatment, plasma levels of inflammatory mediators and DEC were measured, and adverse reactions were recorded. Patients experienced no or mild, moderate, or severe adverse reactions. Increasing pretreatment microfilarial counts were associated with escalating severity of adverse reactions. Plasma concentrations of DEC were not different among patients suffering from varying degrees of illness. Interleukin (IL)-6, IL-10, lipopolysaccharide-binding protein (LBP), and soluble tumor necrosis factor receptors (sTNF-Rs) increased after treatment. IL-6 and LBP, however, showed the strongest association with adverse reactions. Increasing levels of these molecules were closely correlated with the mounting severity of adverse reactions, which raises the possibility that they play an important role in systemic inflammation that arises after DEC treatment of filarial patients.
引用
收藏
页码:564 / 569
页数:6
相关论文
共 30 条
[1]   RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN-2, AND GAMMA-INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL-ANTIBODY IN KIDNEY-TRANSPLANT RECIPIENTS [J].
ABRAMOWICZ, D ;
SCHANDENE, L ;
GOLDMAN, M ;
CRUSIAUX, A ;
VEREERSTRAETEN, P ;
DEPAUW, L ;
WYBRAN, J ;
KINNAERT, P ;
DUPONT, E ;
TOUSSAINT, C .
TRANSPLANTATION, 1989, 47 (04) :606-608
[2]   THE ACUTE-PHASE RESPONSE [J].
BAUMANN, H ;
GAULDIE, J .
IMMUNOLOGY TODAY, 1994, 15 (02) :74-80
[3]   Sepsis and cytokines: Current status [J].
Blackwell, TS ;
Christman, JW .
BRITISH JOURNAL OF ANAESTHESIA, 1996, 77 (01) :110-117
[4]  
CHEN TT, 1964, CHINESE MED J, V2, P393
[5]   THE MAZZOTTI REACTION FOLLOWING TREATMENT OF ONCHOCERCIASIS WITH DIETHYLCARBAMAZINE - CLINICAL SEVERITY AS A FUNCTION OF INFECTION INTENSITY [J].
FRANCIS, H ;
AWADZI, K ;
OTTESEN, EA .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1985, 34 (03) :529-536
[6]   LIPOPOLYSACCHARIDE TOXICITY-REGULATING PROTEINS IN BACTEREMIA [J].
FROON, AHM ;
DENTENER, MA ;
GREVE, JWM ;
RAMSAY, G ;
BUURMAN, WA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1250-1257
[7]   Circulating interleukin 6 and interleukin 10 in community acquired pneumonia [J].
Glynn, P ;
Coakley, R ;
Kilgallen, I ;
Murphy, N ;
O'Neill, S .
THORAX, 1999, 54 (01) :51-55
[8]  
GRUBE BJ, 1994, J BIOL CHEM, V269, P8477
[9]   Adverse reactions following diethylcarbamazine (DEC) intake in 'endemic normals', microfilaraemics and elephantiasis patients [J].
Haarbrink, M ;
Terhell, AJ ;
Abadi, GK ;
Mitsui, Y ;
Yazdanbakhsh, M .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1999, 93 (01) :91-96
[10]   INTERLEUKIN-6 IS INVOLVED IN INTERLEUKIN-1-INDUCED ACTIVITIES [J].
HELLE, M ;
BRAKENHOFF, JPJ ;
DEGROOT, ER ;
AARDEN, LA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (06) :957-959